Hvilken er prisen på Intellipharmaceutics International Inc. (IPCIF)

Prisen på Intellipharmaceutics International Inc. (IPCIF) er $0.15

Hva er markedsverdien på Intellipharmaceutics International Inc. (IPCIF)

Markedsverdien på Intellipharmaceutics International Inc. (IPCIF) er $4.96M

Intellipharmaceutics International Inc. (IPCIF) Utestående Aksjer

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

År	Utestående aksjer	Endre
2026 (TTM)	33.09M	0.00%
2022	33.09M	12.45%
2021	29.43M	24.90%
2020	23.56M	9.18%
2019	21.58M	353.15%
2018	4.76M	53.55%
2017	3.10M	16.16%
2016	2.67M	12.34%
2015	2.38M	3.11%
2014	2.31M	17.18%
2013	1.97M	13.98%
2012	1.73M	15.10%
2011	1.50M	37.47%
2010	1.09M	-51.30%
2008	2.24M	13.63%
2007	1.97M	124.16%
2006	879.29K	10.85%
2005	793.22K	15.41%
2004	687.29K	11.69%
2003	615.38K	27.29%
2002	483.46K	7.69%
2001	448.93K	2.77%
2000	436.82K	49.40%
1999	292.38K	0.00%

År

Utestående aksjer

Endre

2026 (TTM)

33.09M

0.00%

2022

33.09M

12.45%

2021

29.43M

24.90%

2020

23.56M

9.18%

2019

21.58M

353.15%

2018

4.76M

53.55%

2017

3.10M

16.16%

2016

2.67M

12.34%

2015

2.38M

3.11%

2014

2.31M

17.18%

2013

1.97M

13.98%

2012

1.73M

15.10%

2011

1.50M

37.47%

2010

1.09M

-51.30%

2008

2.24M

13.63%

2007

1.97M

124.16%

2006

879.29K

10.85%

2005

793.22K

15.41%

2004

687.29K

11.69%

2003

615.38K

27.29%

2002

483.46K

7.69%

2001

448.93K

2.77%

2000

436.82K

49.40%

1999

292.38K

0.00%

Selskap	Utestående aksjer	Forskjell	Land
Novo Nordisk A/S NVO.US	4.45B	13,340.60%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	667.24%	US
Regeneron Pharmaceuticals, Inc. REGN.US	102.90M	210.95%	US
UCB SA UCB.BR	190.00M	474.14%	BE
Argenx SE ARGX.US	61.42M	85.60%	NL

Selskap

Utestående aksjer

Forskjell

Land